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Abstract
Obese subjects with impaired glucose tolerance (IGT) are more susceptible than healthy individuals to oxidative
stress and cardiovascular disease. This randomised controlled investigation was designed to test the hypothesis
that a-lipoic acid supplementation and exercise training may elicit favourable clinical changes in obese subjects
with IGT. All data were collected from 24 obese (BMI ≥ 30 kg/m
2) IGT patients. Following participant randomisation
into two groups, fasting venous blood samples were obtained at baseline, and before and following intervention.
The first group consisted of 12 participants who completed a 12 week control phase followed by 12 weeks of
chronic exercise at 65% HRmax for 30 minutes a day, 5 days per week, while ingesting 1 gram per day of a-lipoic
acid for 12 weeks. The second group consisted of 12 participants who completed the same 12 week control phase,
but this was followed by 12 weeks of 1 gram per day of a-lipoic acid supplementation only (no exercise). The
main findings show a comparatively greater rate of low density lipoprotein (LDL) oxidation in the group consisting
of a-lipoic acid only (p < 0.05 vs. pre intervention), although total oxidant status was lower post intervention (p <
0.05 vs. baseline) in this group. However, exercise and a-lipoic acid in combination attenuates LDL oxidation.
Furthermore, in the a-lipoic acid supplement plus exercise training group, total antioxidant capacity was
significantly increased (p < 0.05 vs. baseline and pre intervention). Body fat percentage and waist and hip
circumference decreased following exercise training (p < 0.05 vs. post intervention). There were no selective
treatment differences for a range of other clinical outcomes including glycaemic regulation (p > 0.05). These
findings report that a-lipoic acid ingestion may increase the atherogenicity of LDL when ingested in isolation of
exercise, suggesting that in IGT the use of this antioxidant treatment does not ameliorate metabolic disturbances,
but instead may detrimentally contribute to the pathogenesis of atherosclerosis and development of CVD.
However, when a-lipoic acid is combined with exercise, this atherogenic effect is abolished.
Introduction
It is now recognized that the metabolic disturbances asso-
ciated with Type 2 Diabetes (T2D) begin prior to the clini-
cal onset of disease [1]. Specifically, subjects with impaired
glucose tolerance (IGT) have raised low density lipopro-
tein cholesterol (LDL-C), triglyceride (TG), insulin, and
glucose concentrations and impaired vascular function [2].
Thus, IGT can be viewed as a sub-clinical disease accom-
panied with an increased risk of cardiovascular morbidity
and mortality [3]. Lifestyle interventions including the
Diabetes Prevention Program have demonstrated that life-
style modification is a safe and effective approach to pre-
venting T2D and reducing cardiovascular risk in IGT [4].
For example, there is now strong experimental evidence
that exercise training can reduce the risk of developing
T2D, through greater weight loss and control of metabolic
regulation [5]. However, pharmacological treatment is
often preferred as lifestyle interventions are difficult to
maintain long term [6]. Whilst pharmacological treatment
has been successful in improving the metabolic distur-
bances associated with IGT, the safety, tolerability and
adherence to drugs is similar to T2D, with a significant
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with metformin, acarbose and orlistat, whereas thiazolidi-
nediones (TZDs) are associated with significant weight
gain and oedema [6]. Notably, treatment with rosiglitazone
and ramipril is associated with an increased relative risk
for heart failure [6].
Due to the side effects associated with some pharmaco-
logic interventions, the use of a-lipoic acid has been con-
sidered as a method of reducing the increase in reactive
oxygen species (ROS) reported in T2D, which constitute a
major causative factor in atherosclerosis and dysregulated
glucose metabolism [7]. a-lipoic acid (1,2-dithiolane-3-
pentanoic acid (C8H14O2S2) is a natural antioxidant found
in low concentrations in the mammalian diet, and the
most abundant plant sources of a-lipoic acid are spinach,
followed by broccoli and tomatoes [8]. It has been
reported that a-lipoic acid can increase GLUT-4 translo-
cation, leading to improvements in glycaemic control [9],
and this powerful antioxidant may also prevent complica-
tions associated with diabetes such as neuropathy and gly-
cation of proteins [9,10]. Moreover, a-lipoic acid is also
capable of combating ROS, and could potentially prevent
oxidation of LDL-C [11], and decrease atherogenicity and
risk of CVD [11]. To the best of our knowledge, no study
to date has investigated the role of a-lipoic acid supple-
mentation in combination with moderate intensity aerobic
exercise as therapeutic modalities in alleviating the meta-
bolic disturbances associated with IGT. We therefore
hypothesise that a-lipoic acid supplementation alone or
used in combination with exercise would elicit favourable
clinical changes in obese subjects with IGT. We used a
randomised controlled experimental design incorporating
a comprehensive assessment of cardiovascular risk factors
to test this hypothesis.
Methods
Subject characteristics
Following approval from a local Research Ethics Com-
mittee, twenty four (n = 24, 12 males, 12 females) obese
(BMI ≥ 30 kg/m
2, see table 1 for participant characteris-
tics) subjects diagnosed with IGT, following an oral glu-
cose tolerance test (OGTT) [12] were recruited from a
local Diabetic Clinic to participant in this study. Partici-
pants with a family history of sudden cardiac death or a
personal history of cardiovascular or liver complications
were excluded from participation, as determined by
health history questionnaire. Subjects were also excluded
if they smoked, were taking any form of antioxidant sup-
plement, had dyslipidaemia or any type of haematological
disorder. All procedures were conducted in accordance
with The Declaration of Helsinki.
Experimental design
The present study constituted a balanced, randomised
controlled trial.
Preliminary testing
On arrival of participants at the laboratory, their body
mass, stature, body fat percentage (using bioelectrical
impedance; Bodystat 1500, Bodystat, UK) and waist and
hip circumference were measured at baseline and follow-
ing intervention using standard methods. A standard
OGTT (75 g glucose), was administered to all subjects to
confirm impaired glucose tolerance according to clinical
guidelines [12]. Systemic arterial blood pressure (BP) was
measured in the brachial artery using an Omron M5-1
fully automated BP monitor (Surrey, UK). Three readings
were taken at 2 minute intervals following 15 minutes
supine rest and the mean value calculated.
Experimental procedure
Participants were randomly assigned to one of two
experimental groups. Subjects in group one (n =1 2 )
completed a 12 week control phase during which habi-
tual dietary intake and physical activity was monitored
and maintained at consistent levels, followed by 12 weeks
of chronic exercise at 65% predicted HRmax in accor-
dance with ACSM guidelines [13], for 30 minutes a day,
5 days per week, while ingesting 1 g of racemic a-lipoic
acid (Cultech Biospeciality Products, Wales) per day for
12 weeks (1 g a-lipoic acid 7 d
.wk
-1)[ exercise + a-lipoic
acid group]. This exercise intensity was chosen due to its
classification as moderate intensity as outlined by the
ACSM [13] and based on the results of other exercise
Table 1 Age and physiological characteristics of participant groups
Variable Group 1 (n = 12) Group 2 (n=12) Combined (n = 24)
Age (yrs) 56 ± 8 54 ± 8 54 ± 8
Stature (cms) 1.67 ± 0.1 1.68 ± 0.1 1.47 ± 0.5
Body mass (kg) 87 ± 18 93 ± 14 93 ± 14
Body mass index (kg/m
2) 3 2±7 3 3±6 3 3±6
Body fat (%) 47 ± 7 50 ± 1 50 ± 1
Waist circumference (cm) 105 ± 23 105 ± 9 105 ± 9
Hip circumference (cm) 110 ± 14 111 ± 13 110 ± 13
All values are mean ± SD. Each group had 6 male and 6 female subjects.
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equivalent of a brisk walk in this sedentary population
[16]. We assume that all subjects were exercising to the
same metabolic cost throughout the 12 week interven-
tion, as all participating subjects were sedentary, thus
representing a similar level of baseline fitness prior to the
start of the intervention. Following 30 minutes of exer-
cise on a motorised treadmill (Sport Engineering Limited,
UK) to acclimatise to the required walking speed, all par-
ticipants were provided with heart rate monitors (Polar
Electro, Finland) and shown how to operate these to
ensure they were walking at the required intensity for the
duration of the 12 weeks. Subjects in group 2 (n = 12)
completed a 12 week control phase, followed by 12
weeks of 1 g per day of racemic a-lipoic acid supplemen-
tation (1 g a-lipoic acid 7 d
.wk
-1)[ a-lipoic acid only
group]. Subjects were asked to refrain from exercise and
alcohol consumption for 48 hours prior to all experimen-
tal testing, and all testing was conducted between 8.00-
10.00 am to control for inter-subject diurnal variation.
Exercise and supplementation compliance
Subjects were asked to complete weekly exercise diaries
detailing total exercise duration, time of exercise, whether
exercise was performed in isolation or with family mem-
bers/friends and perceived feelings following exercise on a
Likert scale (-5 = very bad, +5 = very good). Subjects were
encouraged to complete walking on flat terrain for the
entire duration of the intervention. Compliance with sup-
plementation was determined by pill counts at the end of
each 4 week period.
Haematology
Sampling
Venous blood was collected following a 12 hour overnight
fast from an antecubital forearm vein following 20 minutes
supine rest at baseline, pre-intervention and 12 weeks post
intervention using the aseptic technique via the Vacutai-
ner method (Becton-Dickinson, Oxford, UK). Blood for
total cholesterol, high density lipoprotein cholesterol
(HDL-C), LDL-C, TG and homocysteine (Hcy) determina-
tion were collected in anaerobic glass vacutainers contain-
ing EDTA and immediately placed on ice, while blood for
glycosylated haemoglobin (% HbA1c), very low density
lipoprotein (VLDL), LDL and HDL isolations, total antiox-
idant capacity (TAC), total oxidant status (TOS) and high
sensitivity C-reactive protein (hs-CRP) were collected in
serum separation glass vacutainers and allowed to clot for
10 minutes in the dark. Blood for glucose determination
was collected in sodium fluoride EDTA tubes. After cen-
trifugation at 3000 rpm at 4°C for 10 minutes, the serum/
plasma samples were stored in aliquots at -80°C. The cho-
lesterol oxidation products were centrifuged at 3500 rpm
for 5 minutes at 4°C and subsequently stored at -80°C. All
samples from the same participant were analysed within
the same batch.
Analyses
Lipid metabolites
Serum total cholesterol, HDL-C, LDL-C and TG concen-
tration (TG) were measured using methods previously
published [17]. Estimates of LDL-C concentration were
calculated using the Friedewald formula [18]. The inter-
assay CVs for total cholesterol, HDL-C and TGs were
0.7%, 3.0% and 2.3% respectively.
Blood glucose and HbA1c
Glucose concentration was determined by the immobilised
enzyme membrane method in conjunction with a Clark
electrode (Leyland Clark, Ohio, USA) on a YSI 2300 analy-
ser (Yellow Springs, USA). The inter-assay CV was < 1%.
HbA1c was assayed using an Adams A1c HA-8160 analy-
ser (ARKRAY, Japan). The inter-assay CV was < 2.0%.
Total homocysteine (tHcy)
tHcy was measured by high-performance liquid chroma-
tography (HPLC) using the method devised by Araki &
Sako [19] and modified by Ubbink and colleagues [20].
The inter-assay CV was 2.6%.
Lipoprotein isolation and oxidation
VLDL, LDL and HDL lipoproteins were isolated via rapid
density gradient ultracentrifugation using a Beckman
TL100 ultracentrifuge with a fixed angle rotor (TL100.3;
Beckman, UK). The procedure was adapted from pre-
viously published methodologies [21,22]. Before under-
going oxidation the lipoprotein samples were standardised
for protein with PBS. VLDL was standardised to 25 μg/ml,
LDL to 50 μg/ml and HDL to 100 μg/ml. Oxidation was
mediated by the addition of copper II chloride (CuCl2;
final concentrations of 35 μMf o rV L D L ,2μMf o rL D L
and 5 μM for HDL). The kinetics of oxidation was moni-
tored in a thermostatically controlled spectrophometer at
37°C by measuring absorbance change at 234 nm on a 96
well Spectra Max 190 plate reader. Data was analysed
using SoftMax Pro Software Package version 4.8 (Molecu-
lar Devices, USA). Following oxidation of each lipoprotein,
time at half max (t 1/2max) in minutes, an equivalent
measure of oxidation susceptibility as lag time was calcu-
lated. The intra and inter-assay CVs were <5%.
Total Oxidant Status (TOS)
Serum total oxidant levels were measured using a modifi-
cation of the method of Erel [23]. Briefly, this assay is
based on the assumption that oxidants present in a biolo-
gical sample can oxidise the ferrous ion-o-dianisidine
complex to ferric ion, and the oxidation reaction is
enhanced by glycerol molecules. The ferric ion forms a
coloured complex with the xylenol orange in an acidic
medium, and the intensity of the colour formed by this
complex can be measured spectrophotometrically at 560
nm. Unknowns were read against a hydrogen peroxide
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terms of μmol H2O2 equivalent per litre (μmol H2O2
Equiv/l). The intra and inter-assay CVs were <5%.
Total Antioxidant Capacity (TAC)
Serum TAC was measured using a modification of the
method of Erel [24]. Briefly, this assay is based on the
principle that reduced 2,2’-azinobis-3-ethylbenzothiazo-
line-6-sulfonic acid (ABTS) molecules are oxidised to the
2,2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid
radical cation (ABTS
.+)u s i n gH 2O2 in acidic medium.
The deep green ABTS
.+ radical cations are stable for a
longer period of time than ABTS molecules, and when
the ABTS
.+ molecules are diluted with a more concen-
trated acetate buffer solution at high pH values, the col-
our is spontaneously bleached by the antioxidants
present in the sample. The bleaching rate is proportional
to the concentrations of antioxidants, which is positively
related to the TAC of a biological sample. This reaction
is spectrophotometrically measured at 660 nm,
unknowns were read against a Trolox standard curve.
Results are expressed in mmol Trolox Equiv/l. The intra
and inter-assay CVs for TAC were <5%.
High sensitivity C-reactive protein hs
CRP was measured on an Aeroset analyser (Abbott
Laboratories, USA) using a CRP high sensitivity assay kit
(Randox laboratories Limited, N Ireland). The formation
of an antibody-antigen complex during the assay proce-
dure results in an increase in turbidity, the extent of which
is measured as the amount of light absorbed at 550 nm.
The CRP concentration was determined from a standard
curve. The inter-assay CV was 1.9%.
Dietary intake assessment Dietary
intake was assessed at six time points (weeks 0, 6, 11, 12,
18 and 24) using four day unweighed diet diaries com-
pleted using a food photography atlas to determine por-
tion size [25]. All dietary information was analysed using
Netwisp nutritional analysis programme (Netwisp, Version
3.0, Tinuvel, 2006).
Statistical analysis
Statistical analysis was performed using the SPSS statistics
package (Version 15.0, SPSS, Woking, UK). A prospective
calculation of power was performed using the equations of
Altman [26]. Data were analysed using parametric statis-
tics following mathematical confirmation of a normal dis-
tribution using Shapiro-Wilk W tests. Baseline, pre and
post intervention data were analysed using a two-way [A x
B ]m i x e da n a l y s i sA N O V Aw h i c hi n c o r p o r a t e do n e
between (group: a-lipoic acid + exercise or a-lipoic acid
only) and one within subjects factor (time: baseline, pre
and post intervention). When a significant interaction
effect was detected, within-participant factors were ana-
lysed using Bonferroni-corrected paired sample t tests.
Between-participant differences were analysed using a
one-way ANOVA with a posterior Tukey honestly signifi-
cant difference test. The alpha level was established at p <
0.05 and all values are reported as mean ± SD unless
otherwise stated.
Results
Exercise and supplementation compliance
All subjects completed the 12 weeks of exercise training
and supplementation, thus representing a return of 100%
for compliance.
Energy intake and composition
There were no significant differences in energy and
micronutrient composition within or between groups
(Table 2).
Body composition and blood pressure
There was a significant decrease in body fat and in waist
and hip circumference in the group undergoing a-lipoic
acid + exercise when compared to baseline and pre
intervention values (p < 0.05 vs. post intervention; Table
3). Systolic and diastolic blood pressure did not change
as a function of time or group (p > 0.05; Table 3).
Oxidation of lipoproteins
There was a comparatively greater rate of LDL oxidation
(ox-LDL) as a function of a-lipoic acid supplementation
only (p < 0.05 vs. pre intervention; Table 4), while LDL
oxidation was unaffected following a-lipoic acid and
exercise. Furthermore, the oxidation potential of VLDL
and HDL were unaffected by intervention in both groups
(p > 0.05).
TOS and TAC
Although TOS was unaffected by a-lipoic acid and exer-
cise treatment (p > 0.05) it was found to be lower post
intervention (p < 0.05 vs. baseline) in the group rando-
mised to a-lipoic acid supplementation (Table 5). Addi-
tionally, TAC was significantly increased in both the
a-lipoic acid and exercise group and the a-lipoic acid only
group (p < 0.05 vs. baseline and pre intervention, for both
groups; Table 5).
Lipids, hs-CRP and homocysteine
Total cholesterol, HDL-C, LDL-C, TGs (mmol/l), hs-
CRP (mg/l) and tHcy (μmol/l) all remained unchanged
throughout in both groups (p > 0.05 for all; Table 3).
Glucose and glycosylated haemoglobin (% HbA1c)
Table 3 shows the effect of exercise and a-lipoic acid
supplementation on blood glucose concentration and
HbA1c. There were no differences in blood glucose or
in % HbA1c following 12 weeks of a-lipoic acid supple-
mentation with or without exercise (p > 0.05).
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Strong experimental evidence indicates that a-lipoic
acid is beneficial for glycaemic regulation [27], in addi-
tion to acting as a powerful dual phase antioxidant in
vivo [8]. The primary purpose of this research was to
ascertain the effects of a-lipoic acid ingestion and 12
weeks of exercise training on glycaemic regulation and
lipoprotein oxidation in obese subjects with IGT. This
study demonstrates that a-lipoic acid ingestion increases
the atherogenicity of LDL cholesterol, suggesting that in
IGT, the use of this antioxidant treatment does not
ameliorate metabolic disturbances, but instead may det-
rimentally contribute to the pathogenesis of athero-
sclerosis and development of CVD. However, when
a-lipoic acid was combined with exercise, this athero-
genic effect was abolished, postulating that moderate
Table 2 Mean dietary intake during control (weeks 0-12) and experimental phase (weeks 12-24) for both groups
Week 0 Week 6 Week 11 Week 12 Week 18 Week 24
a-lipoic acid + exercise group (n = 12)
Total energy (kcal) 1884 (466) 1909 (472) 1892 (616) 1838 (306) 1965 (366) 2002 (324)
Carbohydrate (g) 223 (70) 219 (67) 215 (77) 205(67) 225(65) 227 (58)
Protein (g) 85 (21) 82 (17) 80 (17) 80 (17) 82 (14) 90 (16)
Total fat (g) 71 (24) 74 (25) 74 (33) 71 (14) 78 (14) 74 (17)
Saturated fat (g) 25 (12) 27 (12) 28 (15) 25 (9) 26 (11) 26 (10)
PUFA (g) 13 (3) 13 (5) 12 (4) 13 (6) 15 (6) 14 (5)
MUFA (g) 23 (8) 23 (7) 23 (8) 22 (5) 24 (5) 24 (5)
Cholesterol (mg) 304 (129) 298 (161) 290 (159) 265 (174) 329 (114) 312 (133)
Alcohol (g) 11 (18) 10 (16) 10(16) 7 (13) 5 (13) 8 (17)
a-lipoic acid only group (n = 12)
Total energy (kcal) 2525 (982) 2684 (1088) 2506 (855) 2525 (982) 2684 (1088) 2506 (855)
Carbohydrate (g) 293 (139) 331 (139) 320 (100) 293 (139) 331 (139) 320 (100)
Protein (g) 104 (51) 112 (65) 95 (32) 104 (51) 112 (65) 95 (32)
Total fat (g) 101 (40) 107 (46) 94 (49) 101 (41) 107 (46) 94 (49)
Saturated fat (g) 34 (16) 38 (19) 35 (22) 34 (16) 38 (19) 35 (22)
PUFA (g) 19 (11) 19 (12) 15 (10) 19 (11) 19 (12) 15 (10)
MUFA (g) 34 (14) 33 (14) 29 (11) 34 (14) 33 (14) 29 (11)
Cholesterol (mg) 299 (221) 255 (175) 249 (177) 299 (221) 255 (175) 249 (177)
Alcohol (g) 2 (6) 11 (41) 9 (22) 2 (6) 11 (41) 9 (22)
Values are means ± SD.
Table 3 Biochemical and haemodynamic measures at baseline, pre and post intervention for both groups
Group a-lipoic acid + exercise
(n = 12)
a-lipoic acid only
(n = 12)
Time Baseline Pre intervention Post intervention Baseline Pre intervention Post intervention
Body mass (kg) 87.7 (18.7) 87.3 (18.9) 85.5 (17.4) 93.1 (14.3) 93.1 (14.3) 92.4 (14.0)
BMI (kg/m
2) 31.6 (6.7) 31.4 (6.9) 30.7 (6.4) 32.8 (5.8) 32.8 (5.8) 32.5 (5.7)
Total body fat (%) 46.6 (6.9) 41.6 (5.5) 41.5 (5.4)† 49.8 (11.6) 49.4 (11.2) 49.3 (11.8)
Waist circumference (cms) 105.8 (23.3) 100.6 (13.9) 96.1 (13.9)† 104.9 (9.0) 104.9 (9.0) 102.7 (9.2)
Hip circumference (cms) 109.9 (13.9) 108.8 (16.0) 103.1 (13.1)† 112.5 (12.7) 112.6 (12.8) 111.1 (12.9)
Total cholesterol (mmol
.L
-1) 5.5 (1.0) 5.5 (0.6) 5.2 (1.0) 4.7 (1.2) 4.7 (1.2) 4.8 (1.1)
HDL cholesterol (mmol
.L
-1) 1.2 (0.2) 1.3 (0.2) 1.1 (0.1) 1.1 (0.3) 1.1 (0.3) 1.1 (0.2)
LDL cholesterol (mmol
.L
-1) 3.3 (0.9) 3.4 (0.7) 3.2 (0.9) 3.0 (1.1) 3.0 (1.1) 3.1 (1.1)
Triglycerides (mmol
.L
-1) 1.9 (1.1) 1.7 (0.7) 1.8 (0.8) 1.6 (0.7) 1.6 (0.7) 1.7 (0.7)
hs-CRP (mg/l) 6.2 (5.4) 6.0 (5.7) 6.3 (7.5) 4.6 (5.0) 4.6 (5.0) 4.6 (5.1)
Homocysteine (μmol/l) 11.7 (6.8) 11.2 (3.6) 11.7 (5.1) 12.1 (4.5) 12.1 (4.6) 12.2 (4.6)
Glucose (mmol
.L
-1) 5.9 (0.9) 5.7 (0.6) 5.6 (0.7) 6.1 (1.0) 6.1 (1.0) 6.0 (0.8)
% HbA1c 5.9 (0.3) 5.9 (0.3) 5.7 (0.4) 6.0 (0.5) 6.0 (0.5) 6.2 (1.1)
Systolic BP (mmHg) 143.0 (26.2) 139.2 (20.6) 141.5 (16.9) 141.4 (12.7) 143.2 (12.8) 136.2 (15.4)
Diastolic BP (mmHg) 90.5 (11.6) 88.3 (11.2) 90.3 (11.9) 88.9 (8.6) 90.7 (10) 89.6 (12.7)
Values are means ± SD. † indicates within group differences as a function of time from baseline (p < 0.05)
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Moreover, exercise in combination with a-lipoic acid
significantly decreases total body fat and waist and hip
circumference. However, a-lipoic acid supplementation
alone or in combination with moderate intensity exer-
cise was not effective in improving glycaemic regulation,
as determined by peripheral blood glucose and glycosy-
lated haemoglobin.
Despite no change in HDL or VLDL oxidation and not-
withstanding that total oxidant status decreased with a-
lipoic acid supplementation, the latter demonstrating
moderate antioxidant capability, this study reports that
oxidation of LDL cholesterol was significantly decreased
( a ss h o w nb yad e c r e a s ei nt i m e1 / 2m a x )f o l l o w i n ga-
lipoic acid supplementation, suggesting that a-lipoic acid
may be functioning as a pro-oxidant, increasing LDL
atherogenicity and promoting atherosclerosis. This iso-
lated finding is supported by studies using animal models
to demonstrate that a-lipoic acid and or dihydrolipoic
acid may increase the atherogenicity of LDL cholesterol
[28]. Reported mechanisms for this effect include the gen-
eration and formation of free radical molecular species,
and the superoxide anion is highlighted to be one of the
main protagonists in the initiation of LDL oxidation [29].
Furthermore, the pro-oxidant activity of a-lipoic acid has
previously received attention perhaps due its ability to
react with oxidants and subsequently produce other free
radical species that may propagate a radical chain reaction
and oxidative damage to cells [30].
While a-lipoic acid supplementation in isolation seems
to increase LDL oxidation, and thus susceptibility to
CVD in IGT subjects, a-lipoic acid ingestion in combina-
tion with exercise training abolishes this pro-oxidant
effect. The benefits of exercise training in the prevention
of T2D and CVD are well documented, with a recent
meta-analysis documenting favourable changes to blood
pressure, systemic lipids, vascular function and glucose
control [31]. Likewise, exercise training protects vulner-
able cells against oxidation by an improved enzymatic
antioxidant defence network, involving superoxide dis-
mutase [32], where the up-regulation of isoforms of this
enzyme is activated by the transcription factors nuclear
factor kappaB and mitogen-activated protein kinase [32].
There is a possibility that exercise training protects
against peripheral LDL oxidation in IGT subjects, by a
beneficial adaptation and improved enzymatic antioxi-
dant network, however, as these molecular properties
were not quantified in this work, this hypothesis is
speculative.
The notion that a-lipoic acid contributes towards a ben-
eficial adaptation in glycaemic control was reported by
Estrada et al., [33], where they demonstrated that a-lipoic
acid stimulates glucose transport via GLUT proteins
within the insulin signalling pathway. Although a-lipoic
acid supplementation adversely affected LDL oxidation in
this investigation, this dual phase antioxidant in addition
to exercise had no effect on glycaemic regulation. This
finding was surprising given that both exercise and
a-lipoic acid are independently associated with an increase
in glucose uptake and the reversal of insulin insensitivity
in T2D [34]. An intriguing explanation for the lack of glu-
cose related metabolic change with a-lipoic acid ingestion
may involve the optimal administered dose of a-lipoic
acid. In the present study a 1 g dose of racemic a-lipoic
acid (R- and S- enantiomer) was administered daily for the
duration of the experiment, and we chose this amount
based on the work of Evans et al., [35] where they demon-
strated that 0.9 g of racemic a-lipoic acid for 7 d
.wk
-1 for
6 weeks followed by 1.2 g 7 d
.wk
-1 for 6 weeks significantly
decreased plasma fructosamine by 10% (313 to 282 mmol/
Table 4 Oxidised VLDL, LDL and HDL (time 1/2 max, minutes) at baseline, pre and post intervention for both groups
Group a-lipoic acid + exercise
(n = 12)
a-lipoic acid only
(n = 12)
Time Baseline Pre intervention Post intervention Baseline Pre intervention Post intervention
ox-VLDL 193.2 (6.3) 202.5 (14.5) 205.5 (15.0) 231.5 (12.0) 240.6 (17.1) 229.7 (12.1)
ox-LDL 113.5 (5.0) 114.9 (5.2) 111.7 (3.7) 114.2 (2.5) 118.0 (3.5) 112.7 (2.6)†
ox-HDL 56.0 (4.6) 52.1 (3.4) 56.3 (4.0) 44.8 (1.7) 43.6 (1.5) 42.7 (1.2)
Values are means ± SD. † indicates within group differences as a function of time from baseline (P < 0.05)
Table 5 Total Oxidant Status (TOS) and Total Antioxidant Capacity (TAC) at baseline, pre and post intervention for
both groups
Group a-lipoic acid + exercise
(n = 12)
a-lipoic acid only
(n = 12)
Time Baseline Pre intervention Post intervention Baseline Pre intervention Post intervention
TOS (μmol H202 Equiv/L) 37.0 (8.9) 38.5 (8.2) 35.1 (5.6) 49.7 (9.1) 50.0 (9.5) 38.5 (7.2)†
TAC (mmol.l
-1 Trolox Equiv/l) 1.4 (0.2) 1.4 (0.1) 1.8 (0.3)† 1.3 (0.3) 1.3 (0.3) 1.6 (0.4)†
Values are means ± SD. † indicates within group differences as a function of time from baseline and pre intervention (p < 0.05)
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Page 6 of 9l) in T2D subjects. In addition, 1 g of a-lipoic acid per day
is also considered the maximum daily oral dose achievable
without experiencing side effects such as nausea and gas-
trointestinal stress [35]. Some subjects however, did
experience feelings of nausea during the first week of sup-
plementation which then diminished. It is possible that 1
gram of racemic a-lipoic acid per day as used for 12
weeks in this study was not sufficient to produce favour-
able improvements in glycaemic regulation in systemic
IGT blood. Further aggressive treatment with intrave-
nously administered a-lipoic acid may be required to pre-
vent the metabolic disturbances associated with insulin
resistance. For example, Sergermann et al., [36] success-
fully demonstrated that IV administration of a-lipoic acid
at a rate of 7.5 mg/(100 g body weight
.d) produced a 45%
decrease in plasma triglyceride concentration, but no
improvement in glycaemic control and this was attributed
to the racemic composition of the a-lipoic acid mixture.
Whilst the positive metabolic actions of a-lipoic acid in
improving insulin sensitivity have been reported predomi-
nantly in animal models [8], the R-enantiomer appears to
display a greater effect than the S-enantiomer [33]. There-
fore, perhaps the racemic mixture used in our investiga-
tion was insufficient to elicit favourable changes in
metabolic regulation.
Similar to the lack of effect on glucose regulation with
a-lipoic acid supplementation, there was no antioxidant
effect on LDL oxidation observed with a-lipoic acid, but
in fact increased LDL oxidation. a-Lipoic acid possess the
ability to scavenge a number of ROS whilst also interacting
with other important antioxidants such as ascorbic acid,
a-tocopherol and glutathione in order to produce favour-
able cardiovascular benefits [11]. The availability of in-vivo
antioxidants such as ascorbic acid and a-tocopherol may
explain why a-lipoic acid produced no direct beneficial
antioxidant effect at preventing LDL oxidation. Prior to
intervention in the a-lipoic acid group, total antioxidant
capacity was relatively low compared to values observed
for normoglycaemic individuals (1.34-1.40 mmol.l
-1 Trolox
Equiv/l vs. 1.50-1.77 mmol.l
-1 Trolox Equiv/l in healthy
individuals; Nadeem 2010, unpublished observations).
However, following intervention, total antioxidant capacity
was significantly improved, and this is consistent with
other work demonstrating that a high dose of antioxidants
can favourably increase systemic total antioxidant capacity
[24].
One plausible explanation for a low total antioxidant
capacity at baseline, prior to intervention, is poor dietary
intake. Obesity is characterised by increased intake of
macronutrients (specifically carbohydrate and fat), and
lower than average consumption of fruit and vegetables
rich in antioxidants [37]. By examining the dietary intake
of subjects, it appears that whilst unweighed diet diaries
can provide some useful insight into dietary intake and
habits, they are open to considerable bias. It is likely that
under reporting of macronutrient intake, or over estimat-
ing fruit and vegetable consumption may have occurred
in this population. For example, reported energy intake
for subjects varies from 1884-2506 kcals/day, which
would seem unlikely in obese individuals with a mean
body mass of 93 kg. Similarly, some subjects reported a
moderate fruit and vegetable consumption (3-4 portions
per day), which did not correspond to individual total
antioxidant capacity measurements. Ideally, dietary
intake would be assessed via food photography and pic-
ture plate waste (PPW) which has been successfully used
to avoid the issue of under reporting/over estimating and
is analogous to visual observation [38]. Nonetheless, a
low total antioxidant capacity concentration at baseline,
suggests low fruit and vegetable consumption resulting in
a reduced availability of dietary antioxidants such as
ascorbic acid and a-tocopherol. This would exert a con-
sequential effect on the antioxidant potential of a-lipoic
acid and its ability to recycle endogenous antioxidants
and reduce a-lipoic acid to its oxidised metabolite, dihy-
drolipoic acid [39]. This is supported by results from
Kagan et al., [40] who demonstrated that humans supple-
menting with high doses of a-tocopherol, may cause a
greater recycling of a-tocopherol due to interactions with
ascorbic acid. This work supports the hypothesis that
antioxidant recycling may be a viable mechanism which
may result in decreased oxidation of LDL cholesterol
[40]. Therefore, if IGT subjects have compromised in-
vivo concentrations of primary non-enzymatic antioxi-
dants such as ascorbic acid and a-tocopherol, there is a
profound possibility that a-lipoic acid remained in a
reduced state, as opposed to being oxidised to dihydroli-
poic acid, which is the most effective form for exerting a
protective effect on the oxidation of lipoproteins [39].
Moderate intensity exercise training in combination
with a-lipoic acid ingestion significantly decreases total
body fat and waist and hip circumference. However as no
changes were observed for these parameters in the a-
lipoic acid only group, it is postulated that these changes
were brought about directly by the increased energy
expenditure resulting from exercise training, and this has
been previously reported in T2D [41]. The close relation-
ship between total and central body fat, cardiovascular
disease and hypertension [2] lends further importance to
our findings, and the anthropometric changes confirm
that in obese IGT subjects, a modest amount of exercise
(i.e 30 mins per day) can increase energy expenditure suf-
ficiently, to favourably reduce body composition and thus
decrease susceptibility to CVD.
An obvious limitation of this study is the absence of a
normoglycaemic control group; however, the main aim
of this work was to examine the effects of a-lipoic acid
supplementation in isolation, and in combination with
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Page 7 of 9chronic exercise training in obese subjects with IGT,
and to this end, all parameters were assessed consis-
tently throughout the 12 week control, and subsequent
experimental phase (weeks 12-24). Therefore in essence,
the IGT subjects acted as their own control.
In concluding, whilst reports demonstrate that a-lipoic
acid may possess antioxidant capabilities to improve gly-
caemic regulation and modulate the oxidation of lipopro-
teins [42], the main finding of this investigation shows that
LDL atherogenicity may actually be increased with a-
lipoic acid supplementation, even in the presence of an
enhanced systemic total antioxidant capacity. Our data
thus suggests an increased susceptibility to CVD in IGT
subjects, which may be controlled to some extent by mod-
erate exercise training. Future work should concentrate on
determining whether a-lipoic acid supplementation exerts
a pro-oxidant effect on LDL oxidation in the non-diseased
state and whether this is attenuated by the addition of
exercise. Work is also required to fully ascertain the opti-
mal dose, racemic mixture, and their relationship with
exercise in ameliorating the metabolic disturbances asso-
ciated with insulin resistant conditions such as IGT and
T2D.
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